Additional file 1 of Do iron homeostasis biomarkers mediate the associations of liability to type 2 diabetes and glycemic traits in liver steatosis and cirrhosis: a two-step Mendelian randomization study

Additional file 1: Table S1. The associations of liability to type 2 diabetes and glycemic traits in iron homeostasis biomarkers in our previous study (Liang et al., 2023). Table S2. Description of iron homeostasis biomarkers. Table S3. Information of the data sources used in this study. Table S4. Participant overlap information in the genome-wide associations studies used in this study. Table S5. The genetic instruments information of type 2 diabetes, glycemic traits, iron homeostasis biomarkers, and liver iron after harmonization. Table S6. Genetic instruments information of liability to type 2 diabetes and glycemic traits as exposures. Table S7. Genetic instruments information of iron homeostasis biomarkers as exposures. Table S8. Genetic instruments information of liver iron as exposures. Table S9. Genetic instruments information of liver steatosis, liver cirrhosis, ALT, PDFF, and liver iron as outcomes. Table S10. Genetic information of HbA1c signal classification. Table S11. Study power of this two-step Mendelian randomization study. Table S12. The associations of liability to type 2 diabetes and glycemic traits in liver steatosis, liver cirrhosis, alanine aminotransferase, and proton density fat fraction using Mendelian randomization analysis. Table S13. The associations of HbA1c signal classification in liver steatosis, liver cirrhosis, alanine aminotransferase, and proton density fat fraction using Inverse-variance weighting. Table S14. The associations of iron homeostasis biomarkers in liver steatosis, liver cirrhosis, alanine aminotransferase, and proton density fat fraction using Mendelian randomization analysis. Table S15. The associations of iron homeostasis biomarkers in liver iron using Mendelian randomization analysis. Table S16. The associations of liver iron in liver steatosis, liver cirrhosis, alanine aminotransferase, and proton density fat fraction using Mendelian randomization analysis. Table S17. The associations of HbA1c signal classification in iron homeostasis biomarkers and liver iron using Inverse-variance weighting.附加文件1：表S1。本研究前期工作（Liang等，2023）中2型糖尿病（type 2 diabetes）易感性与血糖性状（glycemic traits）针对铁稳态生物标志物（iron homeostasis biomarkers）的关联分析结果。表S2。铁稳态生物标志物的相关说明。表S3。本研究所用数据来源的相关信息。表S4。本研究采用的全基因组关联研究（genome-wide associations studies）中的参与者重叠信息。表S5。经协调整合后，2型糖尿病、血糖性状、铁稳态生物标志物及肝脏铁的遗传工具变量（genetic instruments）信息。表S6。以2型糖尿病易感性与血糖性状作为暴露因素的遗传工具变量信息。表S7。以铁稳态生物标志物作为暴露因素的遗传工具变量信息。表S8。以肝脏铁作为暴露因素的遗传工具变量信息。表S9。以肝脏脂肪变性（liver steatosis）、肝硬化（liver cirrhosis）、丙氨酸氨基转移酶（alanine aminotransferase，ALT）、质子密度脂肪分数（proton density fat fraction，PDFF）及肝脏铁作为结局的遗传工具变量信息。表S10。糖化血红蛋白（HbA1c）信号分类的遗传信息。表S11。本两步法孟德尔随机化（Mendelian randomization）研究的统计效力信息。表S12。通过孟德尔随机化分析得到的2型糖尿病易感性与血糖性状针对肝脏脂肪变性、肝硬化、丙氨酸氨基转移酶及质子密度脂肪分数的关联分析结果。表S13。通过逆方差加权（Inverse-variance weighting）得到的糖化血红蛋白信号分类针对肝脏脂肪变性、肝硬化、丙氨酸氨基转移酶及质子密度脂肪分数的关联分析结果。表S14。通过孟德尔随机化分析得到的铁稳态生物标志物针对肝脏脂肪变性、肝硬化、丙氨酸氨基转移酶及质子密度脂肪分数的关联分析结果。表S15。通过孟德尔随机化分析得到的铁稳态生物标志物针对肝脏铁的关联分析结果。表S16。通过孟德尔随机化分析得到的肝脏铁针对肝脏脂肪变性、肝硬化、丙氨酸氨基转移酶及质子密度脂肪分数的关联分析结果。表S17。通过逆方差加权得到的糖化血红蛋白信号分类针对铁稳态生物标志物及肝脏铁的关联分析结果。